Arizona Tribune - Universal Biosensors Inc Will Be Participating at the DealFlow Events Microcap Conference

Universal Biosensors' CEO, John Sharman, will deliver a corporate presentation and engage in one-on-one meetings with institutional and individual investors to discuss the company's recent developments, growth strategy, and investment opportunities.

About The Microcap Conference 2025
The Microcap Conference is the largest independent microcap event in the U.S., bringing together top-tier investors and executives from microcap companies. The event offers a platform for companies to showcase their value propositions through presentations, one-on-one meetings, and networking opportunities.

The 2025 event will feature:

• Keynote Speakers: Renowned industry figures, including Jon Ledecky, Co-Owner of the New York Islanders, who will engage in a fireside chat with CNBC's Bob Pisani; plus Tom Gardner, CEO of Motley Fool, who will share insights on investing, market trends, and entrepreneurial success.

• Expert Panels and Presentations: Financial commentators Ron Insana (CNBC) and Charlie Gasparino (FOX Business) will cover critical topics for the US equity markets, from capital formation to regulatory updates and market trends.

• Entertainment Headliner: A special performance by Tom Papa, celebrated comedian and host of Netflix specials, ensuring a memorable evening for attendees.

About Universal Biosensors Inc
Universal Biosensors Inc (UBI) is a global biosensor company and world leader in Point of Care electrochemical sensing. UBI has 20 years of experience developing, manufacturing, and delivering accurate and cost-effective analytical results from a portable handheld analyzer using a fingerstick of blood and other liquid samples.

Our history includes inventing, developing and:

1. partnering (with Johnson&Johnson "LifeScan") one of the biggest blood glucose testing products (OneTouch Verio) which has sold more than 10 billion tests globally;

2. commercialising two generations of Point of Care coagulation PT/INR products (Xprecia) which monitor a patients PT/INR levels within seconds, from a fingerstick sample (sold across 36 countries). US FDA 510(k) and CLIA Waiver approval received for Xprecia Prime in March 2024;

3. commercialising a portable handheld analyzer and 6 assays (Sentia) for the monitoring of six key compounds throughout the wine (Oenology) production process;

4. commercialising a veterinary blood glucose monitoring product (Petrackr) for managing cats and dogs with diabetes.

UBI is developing a range of portable handheld monitoring and detection products in oncology, fertility, environmental and water sensing.

UBI's Corporate strategy is to leverage our existing technology platform to drive immediate growth and develop our next generation technology platform to instigate further growth into larger human and non-human markets.

Media Contact:
Alex Certoma
Associate Director - Corporate
Universal Biosensors Inc
+61 3 9213 9027
[email protected]

SOURCE: Universal Biosensors Inc

H.Romero--AT